TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: tDCS to Decrease Opioid Relapse (UG3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current opioid dependence~* between 21-50 years of age~* recent initiation of buprenorphine or methadone (\<30 days)~Exclusion Criteria:~* current criteria for a DSM-V diagnosis of bipolar disorder, schizophrenia, schizo-affective, schizophreniform, or paranoid disorder~* current suicidality~* evidence of neurocognitive dysfunction~* contraindications for tDCS (e.g seizure disorder)~* probation/parole requirements or an upcoming move that might interfere with protocol participation~* planning to terminate buprenorphine in less than 3 months~* scalp lesions near the tDCS electrode sites

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- tDCS (Type: ACTIVE_COMPARATOR): Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
- sham tDCS (Type: SHAM_COMPARATOR): Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spirometry diagnosed COPD with FEV1/FVC ratio less than 70% and FEV1 less than 80% predicted~* clinically stable and exacerbation free in the past 4 weeks~* history of at least one COPD exacerbation in the past one year~Exclusion Criteria:~* patients allergic or intolerant to NAC~* Recent use of NAC in the past one month~* history of asthma, non COPD respiratory disorders like bronchiectasis, pneumoconiosis or any active pulmonary infection~* patients on long term steroid~* patients on long term oxygen therapy or non invasive ventilation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (600mg twice daily)
- N-acetylcysteine (Type: ACTIVE_COMPARATOR): N-acetylcysteine (600mg twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tasso-SST OnDemand Comparator Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a study participant enrolled in the MURDOCK C3PI Study (Pro00105703), participating in the testing cohort of the study.~* Participants are therefore 18 years of age or older, and~* willing to read and complete the consent process.~Exclusion Criteria:~* No exclusion criteria; however, only up to 100 participants will be enrolled. If more than 100 participants sign consent, some interested participants may not take part in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tasso- SST blood collection (Type: OTHER): About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
- Regular Venipuncture (Type: OTHER): About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identify as MSM: (1) born male who (2) has sex with men~* Age: 18 or older~* Sexual Risk: has had condomless anal sex with 2 or more men or any transactional sex with a man within the past 12-months.~* Vacation: identified an upcoming period of episodic risk away (i.e. vacation) from their home city that will last at least 7 but not more than 14 days during which they anticipate having at least one high-risk sexual event.~* Able and willing to provide informed consent~Exclusion Criteria:~* HIV positive~* Glomerular filtration rate \< 60 mL/min (calculated using the Cockcroft-Gault formula)~* Hepatitis B surface antigen positive~* Symptoms suggestive of acute HIV seroconversion at screening or enrollment~* Have used PrEP or PEP within the previous 3 months~* Currently enrolled in another study involving medications, investigational drug, or medical device~* Has other conditions (based on opinion of investigator or designee) that would preclude informed consent, make the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with study procedures

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Effects of Toradol and Lyrica for Pain Control After Donor Nephrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients anticipating donating a kidney in a live kidney donor transplant.~Exclusion Criteria:~* Patients not receiving a donor nephrectomy~* Pregnant, lactating, or nursing mothers~* Medical allergies or history that would otherwise be contraindicated for of a non-steroidal anti-inflammatory drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Toradol and Lyrica (Type: EXPERIMENTAL): Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
- Placebo and Standard of Care (Type: PLACEBO_COMPARATOR): Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
lnclusion Criteria:~* Male and female patients 20 to less than 80 years of age at the time of informed consent~* Patients histologically or cytologically diagnosed to have peripheral T -cell lymphoma~* Patients with a history of chemotherapy (including PUVA and retinoid) that resulted in relapse, recurrence and treatment resistance (just for the administration of E7777 alone)~* Patients subject to CHOP therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs (just for the administration of E7777 in combination with CHOP therapy)~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1~* No carry-over of beneficial or adverse effects of the prior treatment that may affect the safety evaluation of the investigational drug (excluding Grade 1 neuropathy and alopecia)~Exclusion Criteria:~* Brain metastasis with clinical symptoms which requires treatment~* Serious systemic infection requiring intensive treatment~* Serious complications or histories~* History of hypersensitivity to protein therapeutics~* Known to be positive for HIV antibody, HCV antibody, or HBs antigen~* History of malignancy other than peripheral T-cell lymphoma and less than five years have elapsed since the last remission~* Patients who have undergone allogeneic hematopoietic stem cell transplantation~* Patients with a relapse within 6 months after autologous hematopoietic stem-cell transplantation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- E7777 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes according to the American Diabetes Association criteria for a period less than four months.~* Pancreatic Autoimmunity (positive anti-glutamic acid decarboxylase \[GAD\]; and/or Islet antigen 2 \[anti-IA2\]).~Exclusion Criteria:~* Clinical evidence of malignancy or prior history.~* Pregnancy or desire to become pregnant within 12 months of the study.~* Breastfeeding .~* HIV(+), Hepatitis B (+), Hepatitis C(+).~* Diabetic ketoacidosis at diagnosis.~* Glomerular filtration rate less than 60ml/min.~* Use of immunosuppressors or glucocorticoids.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Adipose tissue-derived stem/stromal cells (Type: EXPERIMENTAL): Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
- Daily 2000 UI of daily oral cholecalciferol (Type: EXPERIMENTAL): To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seroquel in Bipolar Depression Versus Lithium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of bipolar I disorder or bipolar II disorder, currently depressed, aged 18 to 65 years old and outpatient status at enrolment and randomization.~Exclusion Criteria:~* Patients with a current DSM-IV Axis I disorder other than bipolar disorder that is symptomatic or requiring treatment within 6 months of enrolment,~* History of non-response to an adequate treatment~* Patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk~* Pregnancy or lactation~* Clinically relevant disease or clinical finding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 and \</= 80 years of age at time of study inclusion~* Histologically confirmed, previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) according to the WHO classification system~* Patients with an International Prognostic Index (IPI) score 1-5, or IPI score 0 with bulky disease, defined as one lesion \>/= 7.5 cm~* At least one bi-dimensionally measurable lesion defined as \>/= 1.5 cm in its largest dimension on CT scan, PET-CT scan or MRI~* Adequate hematologic function~* Eastern Cooperative Oncology Group (EOCD) performance status \</= 2~Exclusion Criteria:~* Primary or secondary central nervous system lymphoma, histologic evidence of transformation to Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, primary cutaneous DLBCL, or primary DLBCL of the testis~* Transformed lymphoma or follicular lymphoma IIIB~* Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation~* History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin, carcinoma in situ of the cervix, or a malignancy that has been treated without curative intent and has been in remission without treatment for \>/= 5 years prior to enrolment~* Inadequate renal or hepatic function~* Known human immunodeficiency virus (HIV) infection or HIV seropositive status~* Active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection. Patients with occult or prior HBV infection as defined by protocol may be included. Patients positive for HCV antibody are eligible only if polymerase chain reaction testing for HCV ribonucleic acid is negative.~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products~* Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines~* Prior treatment with cytotoxic drugs or rituximab for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A: Rituximab SC (Type: EXPERIMENTAL): None
- B: Rituximab IV (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject was a HF subject who had signed informed consent for MBG311 or MBG312.~* The subject was administered AdreView™ in MBG311 or MBG312.~* The subject completed the late planar imaging assessments (at a minimum) required by the protocols for MBG311 and MBG312, and those images were read and judged diagnostic by at least 2 blinded readers.~* In addition, all subjects must meet 1 of the following 3 inclusion criteria.~* If the subject can be located, he/she provides informed consent to allow the investigator access to medical records and/or gives permission for the investigator to speak to treating physicians.~* If the subject can be located and he/she declines to provide informed consent, the IRB/EC provides a waiver of consent to allow the investigator to record that the subject is alive.~* If the subject cannot be located, the IRB/EC provides a waiver of consent to allow the investigator to access available medical records for care provided subsequent to last date of subject participation in MBG311, MBG312, and/or MBG313 and/or to allow collection of data from publicly available sources.~Exclusion Criteria:~* The subject withdrew or was withdrawn from MBG311 or MBG312 because of a protocol violation.~* The subject underwent heart transplantation during MBG311, MBG312, or MBG313.~* The subject was recorded to have died during MBG311, MBG312, or MBG313.~* The subject voluntarily withdrew from MBG311, MBG312, or MBG313, and the IRB/EC has not provided a waiver to allow recording of subject survival status in such an instance.~* The subject cannot be located, cannot be contacted, and no information can be found to establish survival status beyond the date of last contact in MBG311, MBG312, or MBG313, including information available as a result of an IRB/EC-approved waiver.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages ≥18 years，ECOG ≤ 2，Estimated survival time \> 3 months~* Histologically or Cytologically confirmed metastatic pancreatic adenocarcinoma~* Based on Response Evaluation Criteria In Solid Tumors (RECIST1.1), there should be at least one measurable lesion~* Patients have never received systematical anti-cancer therapy~* Laboratory examination meets the following requirements:White blood cell (WBC) ≥3.0×109/L; absolute neutrophil count (ANC) ≥1.5×109/L; Hemoglobin (HB) ≥90g/L; platelet count(PLT) ≥75×109/L; Total bilirubin (TBIL) ≤1.5× normal upper limit (ULN); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN, if accompanied by liver metastasis, ALT and AST≤5×ULN; Serum creatinine (Cr) ≤1×ULN or creatinine clearance (CCr)≥50ml/min;~* Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) \> 50%~* Patients of childbearing age should take appropriate protective measures before enrollment and during the trial~* Volunteer to join the study, sign the informed consent, have good compliance, and cooperate with follow-up~* Ability to follow the study protocol and follow-up procedures.~Exclusion Criteria:~* Patients have ever received any systematical anti-cancer therapy in the past~* Patients who participated in other clinical trials in the past 4 weeks~* According to the investigator, patients who surgically available or potentially treatable(Patients who voluntarily give up surgical treatment can be enrolled after evaluation by the investigator)~* Patients with moderate ascites requiring drainage~* Patients with CNS metastases and/or carcinomatous meningitis~* Patients with history of other primary malignancies except: 1) complete remission before enrollment for at least 2 years and requiring no additional treatment during the study period; 2) Adequately treated non-melanoma skin cancer or lentiform malignancy with no evidence of disease recurrence; 3) Adequately treated carcinoma in situ with no evidence of disease recurrence;~* Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs~* Patients with bleeding tendency.~* Pregnant or lactating women.~* Drug abuse, clinical or psychological or social factors that impact informed consent or the conduct of the study~* Patients who may be allergic to PD-1 monoclonal antibody, anlotinib, albumin-bound paclitaxel and gemcitabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Flu Vaccine Against Childhood Pneumonia, Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children will be included if they are de jure residents 6 months to 23 months old at the time of first dose vaccination residing in households under surveillance.~Exclusion Criteria:~* Children will be excluded if they have known chronic respiratory, cardiac, or neurological (including seizure disorders) illnesses, are severely malnourished or require hospitalisation for any other reason, are suspected of having tuberculosis (WHO guidelines) \[83\], are known to have egg allergy, or parents withhold consent.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- Influenza vaccine (trivalent inactivated vaccine) (Type: EXPERIMENTAL): None
- Inactivated polio vaccine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetic patients for at least 12 weeks~* HbA1c value between 7.0 and 10.0%~* Body Mass Index (BMI) 20.0 - 45.0 kg/m2~* Investigator adjudicates that a subject is able to discontinue currently taking hypoglycemic agents safely during treatment~Exclusion Criteria:~* Type 1 diabetes mellitus patients~* Serum creatinine \> upper limit of normal~* Proteinuria (albumin/creatinine ratio \> 300mg/g)~* Dysuria and/or urinary tract infection, genital infection~* Significant renal, hepatic or cardiovascular diseases~* Severe gastrointestinal diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP1941 group (Type: EXPERIMENTAL): oral
- placebo group (Type: PLACEBO_COMPARATOR): oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete